Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma ...Middle East

SAN FRANCISCO and SUZHOU, China, March 1, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and...

Hence then, the article about jaypirca pirtobrutinib approved in china for the treatment of relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma was published today ( Monday 02/03/2026 - 03:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Jaypirca® (Pirtobrutinib) Approved in China for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma )

Also on site :

• Makeup Artist Alexis Stone’s Jim Carrey Transformation Claim Divides the Internet
• OPEC+ agrees to raise oil output by 206,000 bpd from April
• NASDAQ: CRWV: Kessler Topaz Meltzer & Check, LLP Announces the Filing of a Securities Fraud Class Action Lawsuit Against CoreWeave, Inc. (CRWV)